PMC:7796052 / 3454-3659 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"134","span":{"begin":161,"end":163},"obj":"Gene"},{"id":"135","span":{"begin":32,"end":34},"obj":"Gene"},{"id":"137","span":{"begin":97,"end":118},"obj":"Disease"}],"attributes":[{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"Gene:3827"},{"id":"A135","pred":"tao:has_database_id","subj":"135","obj":"Gene:3827"},{"id":"A137","pred":"tao:has_database_id","subj":"137","obj":"MESH:D054179"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Nowadays, icatibant is the only BK antagonist approved as therapeutic agent for the treatment of hereditary angioedema [19], in spite of the number of selective BK ligands described in the literature [20]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T11","span":{"begin":108,"end":118},"obj":"Phenotype"}],"attributes":[{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0100665"}],"text":"Nowadays, icatibant is the only BK antagonist approved as therapeutic agent for the treatment of hereditary angioedema [19], in spite of the number of selective BK ligands described in the literature [20]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T23","span":{"begin":0,"end":205},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Nowadays, icatibant is the only BK antagonist approved as therapeutic agent for the treatment of hereditary angioedema [19], in spite of the number of selective BK ligands described in the literature [20]."}